Abeona Therapeutics
ABEO
87 hedge funds and large institutions have $180M invested in Abeona Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 11 reducing their positions, and 18 closing their positions.
281% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $390K
200% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 11
179% more capital invested
Capital invested by funds: $64.6M → $180M (+$115M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
10% more funds holding
Funds holding: 79 → 87 (+8)
0.32% more ownership
Funds ownership: 2.32% → 2.64% (+0.32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$14.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.51M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.64M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.66M |
| 2 |
Millennium Management
New York
|
-$1.26M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$452K |
| 4 |
Two Sigma Investments
New York
|
-$294K |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
-$141K |
ABEO Hedge Fund Activity: Q4 2019 in Review
87 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q4 2019, worth a combined $180M — up 179% from $64.6M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ABEO positions and 18 closed out — a net gain of 8 holders — while 33 added to existing stakes and 11 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $14.8M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.66M sold.
- 87 institutional investors held Abeona Therapeutics (ABEO) as of Q4 2019, up from 79 in Q3 2019.
- Funds reported $180M of Abeona Therapeutics stock for Q4 2019, up 179% quarter-over-quarter.
- 26 funds opened new Abeona Therapeutics positions in Q4 2019 and 18 closed out, a net change of +8 holders.
- The largest Abeona Therapeutics buyer in Q4 2019 was CVI Holdings, an estimated $14.8M added.
- The largest Abeona Therapeutics seller in Q4 2019 was Fidelity Investments, an estimated $1.66M sold.
Based on aggregated 13F filings for Q4 2019.